CA3193994A1 - Methods and compositions for the treatment and prevention of type 1 diabetes - Google Patents

Methods and compositions for the treatment and prevention of type 1 diabetes

Info

Publication number
CA3193994A1
CA3193994A1 CA3193994A CA3193994A CA3193994A1 CA 3193994 A1 CA3193994 A1 CA 3193994A1 CA 3193994 A CA3193994 A CA 3193994A CA 3193994 A CA3193994 A CA 3193994A CA 3193994 A1 CA3193994 A1 CA 3193994A1
Authority
CA
Canada
Prior art keywords
insulin
peptide
mammal
diabetes
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3193994A
Other languages
English (en)
French (fr)
Inventor
Mary S. MORRIS
Richard DI PAOLO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dr Mary Morris & Associates LLC
St Louis University
Original Assignee
Dr Mary Morris & Associates LLC
St Louis University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Mary Morris & Associates LLC, St Louis University filed Critical Dr Mary Morris & Associates LLC
Publication of CA3193994A1 publication Critical patent/CA3193994A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
CA3193994A 2020-10-08 2021-10-05 Methods and compositions for the treatment and prevention of type 1 diabetes Pending CA3193994A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063089122P 2020-10-08 2020-10-08
US63/089,122 2020-10-08
PCT/US2021/053537 WO2022076385A1 (en) 2020-10-08 2021-10-05 Methods and compositions for the treatment and prevention of type 1 diabetes

Publications (1)

Publication Number Publication Date
CA3193994A1 true CA3193994A1 (en) 2022-04-14

Family

ID=81126224

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3193994A Pending CA3193994A1 (en) 2020-10-08 2021-10-05 Methods and compositions for the treatment and prevention of type 1 diabetes

Country Status (7)

Country Link
US (1) US20240041986A1 (https=)
EP (1) EP4225352A4 (https=)
JP (1) JP2023544832A (https=)
CN (1) CN116847869A (https=)
AU (1) AU2021356578A1 (https=)
CA (1) CA3193994A1 (https=)
WO (1) WO2022076385A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3159054A1 (en) * 2019-12-06 2021-06-10 Mary S. MORRIS Methods and compositions for the treatment and prevention of type 1 diabetes

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1409640A (zh) * 1999-12-16 2003-04-09 伊莱利利公司 稳定性改善的多肽组合物
US7279457B2 (en) * 2004-03-12 2007-10-09 Biodel, Inc. Rapid acting drug delivery compositions
US20090023630A1 (en) * 2005-01-31 2009-01-22 Jan Wouter Drijfhout Methods and Means for Use in Diagnostics and Treatment of Diabetes
AU2011202239C1 (en) * 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
US9381247B2 (en) * 2012-04-16 2016-07-05 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain
JP2020143105A (ja) * 2014-01-09 2020-09-10 サノフイＳａｎｏｆｉ インスリンアスパルトの安定化された医薬製剤
US10905727B2 (en) * 2016-01-14 2021-02-02 Intrexon Actobiotics N.V. Compositions and methods for the treatment of type 1 diabetes
US20200087374A1 (en) * 2017-02-06 2020-03-19 Resiliun B.V. Interaction between c-peptides and elastin receptor, a model for understanding vascular disease
EP3589271A4 (en) * 2017-02-28 2021-01-06 Biolingus IP LLC OIL BASED FORMULATIONS FOR SUBLINGUAL AND BUCCAL ADMINISTRATION
CN110662551B (zh) * 2017-06-01 2023-07-18 伊莱利利公司 速效胰岛素组合物
EP3823644A4 (en) * 2018-07-22 2022-06-08 Minovia Therapeutics Ltd. MITOCHONDRIAL AUGMENTATION THERAPY OF PANCREATIC DISEASES
CA3159054A1 (en) * 2019-12-06 2021-06-10 Mary S. MORRIS Methods and compositions for the treatment and prevention of type 1 diabetes

Also Published As

Publication number Publication date
EP4225352A1 (en) 2023-08-16
WO2022076385A1 (en) 2022-04-14
JP2023544832A (ja) 2023-10-25
CN116847869A (zh) 2023-10-03
AU2021356578A9 (en) 2023-07-13
AU2021356578A1 (en) 2023-05-11
EP4225352A4 (en) 2024-01-10
US20240041986A1 (en) 2024-02-08

Similar Documents

Publication Publication Date Title
EP1988100B1 (en) Derivatives of glucagon-like peptide-2 and their therapeutic use
Bhavsar et al. Evolution of exenatide as a diabetes therapeutic
US7049284B2 (en) Glucagon-like peptide-2 and its therapeutic use
US8481490B2 (en) Method of reducing plasma amylase and/or plasma lipase in patients with pancreatitis
EP1928499B1 (en) Use of a dpp-iv inhibitor to reduce hypoglycemic events
JP2017075196A (ja) 医薬組成物、治療方法及びその使用
US20160136246A1 (en) Novel Uses of GLP-1 Receptor Agonists in Patients Treated with Insulin and/or Suffering from Type 1 Diabetes
US12551537B2 (en) Methods and compositions for the treatment and prevention of type 1 diabetes
US20240041986A1 (en) Methods and compositions for the treatment and prevention of type 1 diabetes
Wasilewska et al. Semaglutide-properties, action and chromatographic analysis
US20160002310A1 (en) Modified ingap peptides for treating diabetes
HK40078570A (en) Methods and compositions for the prevention of type 1 diabetes
HK40078570B (en) Methods and compositions for the prevention of type 1 diabetes
US20050176637A1 (en) Peptides
Tatar The role of hepatitis C virus genotypes in development of autoimmune diseases
Qin et al. A Novel Dual-Function GLP-1 Analogue Prevents Type 1 Diabetes Onset in NOD Mice by Controlling the Balance of Treg/Th17 and Th2/Th1
CN120051293A (zh) 用于治疗糖尿病或肥胖症的组合物
Ohneda Effect of Glicentin-Related Peptides on Endocrine Function of Pancreas in Dogs¹
ADLER et al. x. murine diabetes induced through multiple low doses of STZ
HK1125653A (en) Derivatives of glucagon-like peptide-2 and their therapeutic use
HK1153482A (en) Glucagon-like peptide-2 derivatives and their therapeutic use
HK1149720A (en) Glucagon-like peptide-2 and its therapeutic use

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240906

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240906

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240906

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250922

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250922

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20251002

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20251002

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251002

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251205

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20251205

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251205

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251205

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251205

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251210